Background: A history of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity with cross-intolerance to several drugs is common in some patients with coronary artery disease. We present a series of patients with acute coronary syndrome undergoing ASA desensitization prior to a possible stent to evaluate the short- and long-term efficacy and safety. The aim was to evaluate the outcomes of an ASA desensitization protocol developed by our center based on the guidelines proposed by the EAACI drug allergy expert recommendations. Methods: We developed a desensitization protocol that was based on both the patient characteristics and onset of reaction after NSAIDs, including premedication with a leukotriene antagonist and the H1-antagonist antihistamine. The clinical entities were NSAID-induced urticaria and/or angioedema in the absence of chronic spontaneous urticaria (NIUA) and NSAID-exacerbated respiratory disease (NERD). Results: A total of 23 patients were challenged or desensitized with ASA: 19 NIUA and 4 NERD. All patients tolerated the protocol at the different times of 30, 45, 90, and 120 min. The dosages of oral ASA that were given included 10, 21, 41, 81, and 162 mg (cumulative dose 315 mg). One patient reacted during the procedure and 1 during follow-up. Symptoms were limited to the skin without manifestations in other organs. All patients tolerated the required dose of ASA within 30–120 min. Those requiring urgent catheterization were desensitized within 90 min. Conclusions: Our protocol addresses challenge or desensitization with the contribution of a specialist allergist. It provides an effective, dynamic, safe, and short administration of 81 mg or higher of ASA in patients with a history of NSAID hypersensitivity with skin involvement.

Keywords:
Nonsteroidal anti-inflammatory drugs, Challenge, Desensitization, Coronary angioplasty, High-risk patients
1.
Bartolucci AA, Tendera M, Howard G: Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107: 1796–1801.
2.
Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.
3.
Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665–1671.
4.
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A: 2014 ESC/EACTS guidelines on myocardial revascu-larization. EuroIntervention 2015; 10: 1024–1094.
5.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons: 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: 2354–2394.
6.
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH: 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574–e651.
7.
Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233–1243.
8.
Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G: A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667–2674.
9.
Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Nizankowska-Mogilnicka E, Romano A, Sanchez-Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011; 66: 818–829.
10.
Castells M: Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006; 6: 476–481.
11.
Joint Task Force on Practice Parameters; American Academy of Allergy Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology: Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105: 259–273.
12.
Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ: Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 2000; 105: 997–1001.
13.
Silberman S, Neukirch-Stoop C, Steg PG: Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005; 95: 509–510.
14.
Lee JK, Tsui KL, Cheung CY, Chau CH, Chan HL, Wu KL, Cheung GS, Choi MC, Chan KK, Li SK: Aspirin desensitisation for Chinese patients with coronary artery disease. Hong Kong Med J 2013; 19: 207–213.
15.
Hobbs L, Lyle B: Rapid oral aspirin desensitization for patients with aspirin allergy requiring dual antiplatelet therapy. Conn Med 2008; 72: 87–89.
16.
Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA, Mihalcsik L, Gavazzi A: Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol 2008; 101: 786–789.
17.
Christou A, Kafkas N, Marinakos A, Katsanos S, Papanikitas K, Patsilinakos S: Rapid desensitisation of patients with aspirin allergy who undergo coronary angioplasty. Hellenic J Cardiol 2011; 52: 307–310.
18.
Cortellini G, Testi S, Severino M, Chechi T, Iorno ML, Santucci A, Corvetta A, Piovaccari G, Santarelli A, Franco N, Canonica GW, Passalacqua G: Aspirin challenge/desensitisation before coronary stenting in subjects with history of hypersensitivity: a pragmatic approach. Eur Ann Allergy Clin Immunol 2012; 44: 160–162.
19.
Córdoba-Soriano JG, Corbi-Pascual M, Lopez-Neyra I, Navarro-Cuartero J, Hidalgo-Olivares V, Barrionuevo-Sanchez MI, Prieto-Mateos D, Gutierrez-Diez A, Gallardo-Lopez A, Fuentes-Manso R, Gomez-Perez A, Lafuente-Gormaz C, Jimenez-Mazuecos J: Early aspirin desensitization in unstable patients with acute coronary syndrome: short and long-term efficacy and safety. Eur Heart J Acute Cardiovasc Care 2016; 5: 41–50.
20.
McMullan KL, Wedner HJ: Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol 2013; 36: 25–30.
21.
De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P: Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation: a single-center experience. Int J Cardiol 2013; 167: 561–563.
22.
Díez-Villanueva P, Antuna P, Mugica MV, Belver MT, Aguilar R, Alfonso F: Aspirin desensitization in patients with acute coronary syndrome. Med Intensiva 2016; 40: 452–454.
23.
Cortellini G, Romano A, Santucci A, Barbaud A, Bavbek S, Bignardi D, Blanca M, Bonadonna P, Costantino MT, Laguna JJ, Lombardo C, Losappio LM, Makowska J, Nakonechna A, Quercia O, Pastorello EA, Patella V, Terreehorst I, Testi S, Cernadas JR, Dionicio Elera J, Lippolis D, Voltolini S, Grosseto D; EAACI Drug Interest Group on Challenge and Desensitization Procedures with Aspirin in CAD: Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity. Allergy 2017; 72: 498–506.
24.
Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, Lettieri C, Bossi I, Colombo P, Rigattieri S, Dossena C, Anzuini A, Capodanno D, Senni M, Angiolillo DJ: Aspirin desensitization in patients with coronary artery disease: results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv 2017; 10:e004368.
25.
Dona I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nunez I, Gomez F, Salas M, Rondon C, Canto MG, Blanca M: Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol 2012; 22: 363–371.
26.
Dona I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J, Rosado A, Rondon C, Campo P, Agundez JA, Blanca M, Canto G: Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy 2011; 41: 86–95.
27.
Kowalski ML, Woessner K, Sanak M: Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol 2015; 136: 245–251.
28.
Kowalski ML, Wardzynska A, Makowska JS: Clinical trials of aspirin treatment after desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am 2016; 36: 705–717.
29.
Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA: Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004; 292: 3017–3023.
30.
Ortega N, Dona I, Moreno E, Audicana MT, Barasona MJ, Berges-Gimeno MP, Blanca-Lopez N, Lobera T, Padial A, Rosado A, Torres MJ: Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 2014; 24: 308–323.
31.
Canto MG, Andreu I, Fernandez J, Blanca M: Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol 2009; 9: 293–297.
32.
Bianco M, Bernardi A, D’Ascenzo F, Cerrato E, Omede P, Montefusco A, DiNicolantonio JJ, Zoccai GB, Varbella F, Carini G, Moretti C, Pozzi R, Gaita F: Efficacy and safety of available protocols for aspirin hypersensitivity for patients undergoing percutaneous coronary intervention: a survey and systematic review. Circ Cardiovasc Interv 2016; 9:e002896.
33.
Blumenthal KG, Lai KH, Huang M, Wallace ZS, Wickner PG, Zhou L: Adverse and hypersensitivity reactions to prescription nonsteroidal anti-inflammatory agents in a large health care system. J Allergy Clin Immunol Pract 2017; 5: 737–743.
34.
Woessner KM, Simon RA: Cardiovascular prophylaxis and aspirin “allergy.” Immunol Allergy Clin North Am 2013; 33: 263–274.
35.
Dona I, Barrionuevo E, Salas M, Cornejo-Garcia JA, Perkins JR, Bogas G, Prieto A, Torres MJ: Natural evolution in patients with nonsteroidal anti-inflammatory drug-induced urticaria/angioedema. Allergy 2017; 72: 1346–1355.
36.
Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, Kowalski ML, Setkowicz M, Ring J, Brockow K, Bachert C, Wohrl S, Dahlen B, Szczeklik A: EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62: 1111–1118.
37.
Williams AN, Simon RA, Woessner KM, Stevenson DD: The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol 2007; 120: 273–277.
38.
Hope AP, Woessner KA, Simon RA, Stevenson DD: Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009; 123: 406–410.
39.
Stevenson DD, White AA: Aspirin desensitization in aspirin-exacerbated respiratory disease: consideration of a new oral challenge protocol. J Allergy Clin Immunol Pract 2015; 3: 932–933.
40.
White A, Ludington E, Mehra P, Stevenson DD, Simon RA: Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol 2006; 97: 688–693.
41.
Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, Freeman A, Seiberling M, Merz M, Cheng H: Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 1997; 18: 769–777.
42.
Cook KA, White AA: Rapid aspirin challenge in patients with aspirin allergy and acute coronary syndromes. Curr Allergy Asthma Rep 2016; 16: 11.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.